Daily Archives: June 12, 2020

PRA Enhances COVID-19 Monitoring Program with Integration of Microsoft Healthcare Bot Service

RALEIGH, N.C., June 12, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service. Users of PRA’s Health Harmony digital platform who enroll in their organization’s COVID-19 Monitoring Program can use the AI-based chatbot, which can recognize and respond to COVID-19-related questions, to enhance their own COVID-19 care.

Through a series of conversational questions and interactions within PRA’s Health Harmony digital health platform, the COVID-19 chatbot compares users’ symptoms to U.S. Centers for Disease Control guidance and then recommends one of three available COVID-19 programs in which they should enroll. For users of the Health Harmony app, the enrollment experience becomes more personalized and is more accurate in determining the level of COVID-19 care needed. For organizations that have implemented PRA’s COVID-19 Monitoring Program, the integration allows them to understand patient flow and to monitor, educate and individualize care with greater agility.

“Collaborating closely with leading edge companies like Microsoft, PRA is uniquely positioned to deliver innovative new models of care to patients as their needs evolve, especially in times of crisis and uncertainty,” said Kent Thoelke, EVP and Chief Scientific Officer at PRA Health Sciences. “With PRA’s Health Harmony app in their hands, patients can track signs, symptoms and self-manage their own COVID-19-related care, but if symptoms escalate, remote monitoring and the help obtained from a healthcare professional can make all the difference. PRA is giving patients more control and better access to personalized healthcare, right from their own devices and on their own schedule.”

Last month, PRA rolled out the program and the Health Harmony mobile app, with the integration of the COVID-19 Healthcare Bot service, to more than 7,000 employees in the United States. Since March, thousands of users from around the globe have downloaded PRA’s Health Harmony app and enrolled in the COVID-19 Monitoring Program. As part of the program, users can track their own COVID-19 symptoms and educate themselves about the disease. The COVID-19 Monitoring Program – available commercially to employers, payers, providers and health systems – offers three levels of support:

  • The educational program, which provides vital sign tracking, prevention techniques and mental health support for those who are asymptomatic.
  • The quarantine program, which delivers insights on what to watch for, addresses feelings of fear and isolation, and connects with a healthcare professional for those who have been exposed to COVID-19.
  • The in-depth monitoring program, which addresses symptom management, frequent monitoring by a healthcare professional and care coordination for those who have been diagnosed with COVID-19 and who are still at home.

“Healthcare and clinical research should be easily accessible to all people and tailored to fit their unique needs,” said Jean Gabarra, General Manager, Health AI at Microsoft. “When technology like Microsoft’s COVID-19 Healthcare Bot and a user-friendly interface like the Health Harmony app can be combined with the insights and expertise of a global healthcare intelligence partner like PRA, patients’ health and wellbeing will benefit tremendously.”

To learn more about how PRA is delivering technology and R&D solutions to employers, payers and providers during COVID-19, please visit www.prahs.com/covid-19. For more information on the COVID-19 Monitoring Program and Health Harmony mobile platform, visit https://www.careinnovations.com/.

About PRA Health Sciences

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

MEDIA INQUIRIES: Laurie Hurst, Sr. Director, Communications and Public Relations
hurstlaurie@prahs.com | +1 (919) 786-8435

PRA Enhances COVID-19 Monitoring Program with Integration of Microsoft Healthcare Bot Service

RALEIGH, N.C., June 12, 2020 (GLOBE NEWSWIRE) — PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the enhancement of its commercial Health Harmony COVID-19 Monitoring Program with the integration of the Microsoft Healthcare Bot service. Users of PRA’s Health Harmony digital platform who enroll in their organization’s COVID-19 Monitoring Program can use the AI-based chatbot, which can recognize and respond to COVID-19-related questions, to enhance their own COVID-19 care.

Through a series of conversational questions and interactions within PRA’s Health Harmony digital health platform, the COVID-19 chatbot compares users’ symptoms to U.S. Centers for Disease Control guidance and then recommends one of three available COVID-19 programs in which they should enroll. For users of the Health Harmony app, the enrollment experience becomes more personalized and is more accurate in determining the level of COVID-19 care needed. For organizations that have implemented PRA’s COVID-19 Monitoring Program, the integration allows them to understand patient flow and to monitor, educate and individualize care with greater agility.

“Collaborating closely with leading edge companies like Microsoft, PRA is uniquely positioned to deliver innovative new models of care to patients as their needs evolve, especially in times of crisis and uncertainty,” said Kent Thoelke, EVP and Chief Scientific Officer at PRA Health Sciences. “With PRA’s Health Harmony app in their hands, patients can track signs, symptoms and self-manage their own COVID-19-related care, but if symptoms escalate, remote monitoring and the help obtained from a healthcare professional can make all the difference. PRA is giving patients more control and better access to personalized healthcare, right from their own devices and on their own schedule.”

Last month, PRA rolled out the program and the Health Harmony mobile app, with the integration of the COVID-19 Healthcare Bot service, to more than 7,000 employees in the United States. Since March, thousands of users from around the globe have downloaded PRA’s Health Harmony app and enrolled in the COVID-19 Monitoring Program. As part of the program, users can track their own COVID-19 symptoms and educate themselves about the disease. The COVID-19 Monitoring Program – available commercially to employers, payers, providers and health systems – offers three levels of support:

  • The educational program, which provides vital sign tracking, prevention techniques and mental health support for those who are asymptomatic.
  • The quarantine program, which delivers insights on what to watch for, addresses feelings of fear and isolation, and connects with a healthcare professional for those who have been exposed to COVID-19.
  • The in-depth monitoring program, which addresses symptom management, frequent monitoring by a healthcare professional and care coordination for those who have been diagnosed with COVID-19 and who are still at home.

“Healthcare and clinical research should be easily accessible to all people and tailored to fit their unique needs,” said Jean Gabarra, General Manager, Health AI at Microsoft. “When technology like Microsoft’s COVID-19 Healthcare Bot and a user-friendly interface like the Health Harmony app can be combined with the insights and expertise of a global healthcare intelligence partner like PRA, patients’ health and wellbeing will benefit tremendously.”

To learn more about how PRA is delivering technology and R&D solutions to employers, payers and providers during COVID-19, please visit www.prahs.com/covid-19. For more information on the COVID-19 Monitoring Program and Health Harmony mobile platform, visit https://www.careinnovations.com/.

About PRA Health Sciences

PRA Health Sciences is one of the world’s leading global contract research organizations by revenue, providing outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries. PRA’s global clinical development platform includes more than 75 offices across North America, Europe, Asia, Latin America, South Africa, Australia and the Middle East and more than 17,500 employees worldwide. Since 2000, PRA has participated in approximately 4,000 clinical trials worldwide. In addition, PRA has participated in the pivotal or supportive trials that led to U.S. Food and Drug Administration or international regulatory approval of more than 95 drugs. To learn more about PRA, please visit www.prahs.com.

INVESTOR INQUIRIES: InvestorRelations@prahs.com

MEDIA INQUIRIES: Laurie Hurst, Sr. Director, Communications and Public Relations
hurstlaurie@prahs.com | +1 (919) 786-8435

Philips launches obstetrics monitoring solution to support clinicians and expectant mothers during COVID-19 pandemic

June 12, 2020

  • Under new April 2020 FDA guidance [1], the Avalon CL Fetal and Maternal Pod and Patch are now available in the U.S., in addition to existing countries in Europe, Australia, New Zealand and Singapore, to support fetal and maternal monitoring
  • Integrated with Philips’ comprehensive obstetrical care portfolio, the new offering has the potential to reduce mother and clinician risk of exposure to COVID-19, in hospital and in the home
  • Solution complements Philips innovative Remote Patient Monitoring suite designed to transform care for at-risk populations

Amsterdam, the NetherlandsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an addition to its remote patient monitoring suite supporting at-risk populations during the COVID-19 emergency. The new wireless Avalon CL Fetal and Maternal Pod and Patch aim to reduce unnecessary physical interactions between clinicians and patients, which is of particular importance during the COVID-19 pandemic. The patch is part of a broader innovative high-risk pregnancy solution which includes Philips perinatal analytics, and visualization software as well as an ultra-portable battery-operated fetal monitor.

Up to half a million women may deliver their babies while infected with COVID-19 in 2020. Additionally, pregnant women who have not been diagnosed with COVID-19 are interested in ways they can minimize their time in a hospital to limit their exposure to the disease. While clinicians are treating COVID-19 patients in isolation rooms, and accommodating home visits and births when possible, properly managing patient care while reducing the risk of exposure for care providers requires tools that enable remote monitoring of vitals.

The Fetal and Maternal Pod and Patch allow for continuous, non-invasive monitoring of maternal heart rate, fetal heart rate, and uterine activity with a single-use, 48-hour, disposable electrode patch placed on the mother’s abdomen. The patch is designed to be placed on the patient by a clinician only once, unlike traditional elastic belts and sensors that require frequent repositioning.

“Remote monitoring during labor has always provided multiple benefits to expectant mothers, including comfort, mobility, and flexibility. But during the COVID-19 pandemic, the need for mobile solutions during pregnancy is greater than ever,” said Peter Ziese, General Manager, Monitoring & Analytics at Philips. “Philips has been dedicated to providing the best quality care for expectant mothers for more than fifty years. This new solution builds on our commitment to provide integrated continuous monitoring capabilities for high risk pregnancies. With this new patch, clinicians now have access to an innovative tool to help monitor pregnant women during COVID-19, helping to deliver comfort to these mothers during a particularly stressful time.”

“The fact that the new sensors are disposable and don’t require constant repositioning has been particularly useful for us in the peak of the COVID-19 wave in March and April in Lisbon,” said Prof. Dr. Diogo Ayres-de-Campos, University of Lisbon, and President-Elect of the European Association of Perinatal Medicine (EAPM).

The Philips OB solution consists of the Avalon Fetal monitoring portfolio, featuring Philips proprietary Smart Pulse technology, and an obstetrical information management system for continuous data flow to the EMR, which includes:

  • The Avalon Fetal and Maternal Pod and Patch: single-use disposable patch and reusable pod placed on the expectant mother’s abdomen to capture fetal and maternal heart rate, and uterine activity through ECG and EMG signals, without the need for constant repositioning;
  • Avalon CL Transducer System: provides cableless monitoring with the Avalon Fetal Monitors to give expectant mothers freedom to move during labor, while measuring up to three fetuses. The Avalon CL Wide Range Pod leverages the hospital’s wireless LAN installation to allow mothers to expand the area of ambulation, by extending monitoring of all cableless measurements to the full reach of the WLAN.;
  • IntelliSpace Perinatal: obstetrical surveillance and information management system designed for use from antepartum visit through labor, delivery, and postpartum care. Patient data automatically displays and streams to the electronic medical record (EMR). ISP Revision K in combination with IntelliVue XDS Remote Display functionality offers the ability to control the Fetal Monitor remotely.

The Avalon Fetal and Maternal Pod and Patch received CE Mark clearance in 2019 and is available in many EU countries [2], as well as Australia, New Zealand and Singapore.

Philips has a comprehensive portfolio of services and solutions which can help to support the delivery of high-quality care to COVID-19 patients. It includes secure, connected and intelligent approaches to diagnosis, treatment and predictive monitoring in the hospital, plus screening, remote patient monitoring and care at home. With healthcare under more pressure than ever before, Philips’ telehealth and AI-enabled data analytics can help support workflows, facilitate remote collaboration and optimize resources. Philips’ COVID-19-related solutions are designed for rapid deployment and scalability. For more information on how Philips is addressing COVID-19 globally, please visit the Philips centralized COVID-19 hub.

[1] https://www.fda.gov/media/137286/download.
[2] The Avalon Fetal and Maternal Pod and Patch is available across Europe in the Benelux, DACH, UK&I, Nordics, CEE and Iberia markets.

For more information, please contact:
Kathy O’Reilly
Philips Global Press Office
Tel: +1 978-221-8919
Email: kathy.oreilly@philips.com
Twitter: @kathyoreilly

Silvie Casanova
Philips North America
Tel: +1 978 659 7467
E-mail: Silvie.casanova@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Philips launches obstetrics monitoring solution to support clinicians and expectant mothers during COVID-19 pandemic

June 12, 2020

  • Under new April 2020 FDA guidance [1], the Avalon CL Fetal and Maternal Pod and Patch are now available in the U.S., in addition to existing countries in Europe, Australia, New Zealand and Singapore, to support fetal and maternal monitoring
  • Integrated with Philips’ comprehensive obstetrical care portfolio, the new offering has the potential to reduce mother and clinician risk of exposure to COVID-19, in hospital and in the home
  • Solution complements Philips innovative Remote Patient Monitoring suite designed to transform care for at-risk populations

Amsterdam, the NetherlandsRoyal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced an addition to its remote patient monitoring suite supporting at-risk populations during the COVID-19 emergency. The new wireless Avalon CL Fetal and Maternal Pod and Patch aim to reduce unnecessary physical interactions between clinicians and patients, which is of particular importance during the COVID-19 pandemic. The patch is part of a broader innovative high-risk pregnancy solution which includes Philips perinatal analytics, and visualization software as well as an ultra-portable battery-operated fetal monitor.

Up to half a million women may deliver their babies while infected with COVID-19 in 2020. Additionally, pregnant women who have not been diagnosed with COVID-19 are interested in ways they can minimize their time in a hospital to limit their exposure to the disease. While clinicians are treating COVID-19 patients in isolation rooms, and accommodating home visits and births when possible, properly managing patient care while reducing the risk of exposure for care providers requires tools that enable remote monitoring of vitals.

The Fetal and Maternal Pod and Patch allow for continuous, non-invasive monitoring of maternal heart rate, fetal heart rate, and uterine activity with a single-use, 48-hour, disposable electrode patch placed on the mother’s abdomen. The patch is designed to be placed on the patient by a clinician only once, unlike traditional elastic belts and sensors that require frequent repositioning.

“Remote monitoring during labor has always provided multiple benefits to expectant mothers, including comfort, mobility, and flexibility. But during the COVID-19 pandemic, the need for mobile solutions during pregnancy is greater than ever,” said Peter Ziese, General Manager, Monitoring & Analytics at Philips. “Philips has been dedicated to providing the best quality care for expectant mothers for more than fifty years. This new solution builds on our commitment to provide integrated continuous monitoring capabilities for high risk pregnancies. With this new patch, clinicians now have access to an innovative tool to help monitor pregnant women during COVID-19, helping to deliver comfort to these mothers during a particularly stressful time.”

“The fact that the new sensors are disposable and don’t require constant repositioning has been particularly useful for us in the peak of the COVID-19 wave in March and April in Lisbon,” said Prof. Dr. Diogo Ayres-de-Campos, University of Lisbon, and President-Elect of the European Association of Perinatal Medicine (EAPM).

The Philips OB solution consists of the Avalon Fetal monitoring portfolio, featuring Philips proprietary Smart Pulse technology, and an obstetrical information management system for continuous data flow to the EMR, which includes:

  • The Avalon Fetal and Maternal Pod and Patch: single-use disposable patch and reusable pod placed on the expectant mother’s abdomen to capture fetal and maternal heart rate, and uterine activity through ECG and EMG signals, without the need for constant repositioning;
  • Avalon CL Transducer System: provides cableless monitoring with the Avalon Fetal Monitors to give expectant mothers freedom to move during labor, while measuring up to three fetuses. The Avalon CL Wide Range Pod leverages the hospital’s wireless LAN installation to allow mothers to expand the area of ambulation, by extending monitoring of all cableless measurements to the full reach of the WLAN.;
  • IntelliSpace Perinatal: obstetrical surveillance and information management system designed for use from antepartum visit through labor, delivery, and postpartum care. Patient data automatically displays and streams to the electronic medical record (EMR). ISP Revision K in combination with IntelliVue XDS Remote Display functionality offers the ability to control the Fetal Monitor remotely.

The Avalon Fetal and Maternal Pod and Patch received CE Mark clearance in 2019 and is available in many EU countries [2], as well as Australia, New Zealand and Singapore.

Philips has a comprehensive portfolio of services and solutions which can help to support the delivery of high-quality care to COVID-19 patients. It includes secure, connected and intelligent approaches to diagnosis, treatment and predictive monitoring in the hospital, plus screening, remote patient monitoring and care at home. With healthcare under more pressure than ever before, Philips’ telehealth and AI-enabled data analytics can help support workflows, facilitate remote collaboration and optimize resources. Philips’ COVID-19-related solutions are designed for rapid deployment and scalability. For more information on how Philips is addressing COVID-19 globally, please visit the Philips centralized COVID-19 hub.

[1] https://www.fda.gov/media/137286/download.
[2] The Avalon Fetal and Maternal Pod and Patch is available across Europe in the Benelux, DACH, UK&I, Nordics, CEE and Iberia markets.

For more information, please contact:
Kathy O’Reilly
Philips Global Press Office
Tel: +1 978-221-8919
Email: kathy.oreilly@philips.com
Twitter: @kathyoreilly

Silvie Casanova
Philips North America
Tel: +1 978 659 7467
E-mail: Silvie.casanova@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

Flash flood inundates homes in Gorontalo, impacts 1,150 residents

Gorontalo A total of 1,150 people were affected by flooding in Padebuolo and Ipilo, Kota Timur Sub-district, in Gorontalo City, Gorontalo Province, on Thursday night.

The floodwaters, reaching heights of nearly 1.5 meters, submerged residential areas, as Bone River overflowed its bank, Kota Timur Sub-district Head Eladona Oktamina Sidiki revealed here.

The local authorities deployed rubber boats to help the displaced people move to higher grounds.

“A joint team and also residents quickly evacuated the flood victims,” he stated.

The flooding affected 150 families comprising 500 people in Ipilo and 200 families comprising 650 people in Padebuolo.

 

Source: ANTARA News